Biochimpharm Invests GEL 17.5 Million in Modernizarion of Phage Enterprise

The manufacturer of phage preparations, Biochimpharm, will invest about 17.5 million GEL in the modernization of the historical phage enterprise (1934) and ensuring compliance with the European production standard.

As part of the investment, it is planned to equip the company's historic enterprise with unique, high-tech production lines for the Caucasus region, which will enable the company to increase productivity, create additional jobs, introduce the GMP standard and internationalize.

Photo: Bacteriophage Institute 1934, Tbilisi

"At this stage, the company exports phages to 8 countries. This investment will enable us to export to more than 50 additional countries. The process of internationalization would be very difficult without the support of EU4Business, EBRD, Produce in Georgia, FAO and other local or international support, especially given the global pandemic caused by Covid-19 and the ensuing economic crisis. I think it is a turning point in the history of our company and we have high hopes that this event will significantly contribute to the development of not only biochemicals, but also phages and biopharmaceuticals in Georgia, our each team member is very proud of that, "the company representative said.

Biochimpharm is a Georgian biopharmaceutical company, which is engaged in the creation and production of phage preparations. The company is based on the historical production base of bacteriophage (1934), has a unique know-how of phage production and 80 years of accumulated experience. "Biochimpharm" currently employs 45 people, holds 2 international patents, exports phages to 8 countries and is an ISO 9001-2015 certified company.

Translated from Entrepreneur